Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Five Below Inc (FIVE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Five Below Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Five Below Inc trades at $189.77 (market cap $10.47B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3.8× Five Below Inc's market cap, and Five Below Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | FIVE | |
|---|---|---|
Market Cap | $39.89B | $10.47B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $247.71 |
52-Week Low | $278.09 | $129.46 |
Enterprise Value | $38.15B | $11.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
FIVE trades at $189.39, up 2.8% today, with a bearish technical signal but strong fundamentals including a 36.81% gross margin and 21.13% ROE. Recent earnings beats and a 60% analyst buy rating support momentum, while expansion to 2,000 stores (GlobeNewsWire, July 9, 2026) highlights growth. The stock faces resistance near $191 with net cash flow positive at $152 million in 2025.
Outlook remains positive with a $252.09 consensus target, though risks include margin pressure from 2025's 6.54% net margin and bearish moving averages. Growth drivers are digital marketing and store openings, but investor caution is warranted near technical resistance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →
